These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32433187)

  • 1. Perils of Antithrombotic Transitions: Effect of Oral Factor Xa Inhibitors on the Heparin Antifactor Xa Assay.
    Ahuja T; Yang I; Huynh Q; Papadopoulos J; Green D
    Ther Drug Monit; 2020 Oct; 42(5):737-743. PubMed ID: 32433187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-factor Xa as the preferred assay to monitor heparin for the treatment of pulmonary embolism.
    Zhu E; Yuriditsky E; Raco V; Katz A; Papadopoulos J; Horowitz J; Maldonado T; Ahuja T
    Int J Lab Hematol; 2024 Apr; 46(2):354-361. PubMed ID: 37989523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Managing Factor Xa Inhibitor to Unfractionated Heparin Transitions by aPTT Versus a Treatment Guideline Utilizing Heparin Anti-Xa Levels.
    Dingus SJ; Smith AR; Dager WE; Zochert S; Nothdurft SA; Gulseth MP
    Ann Pharmacother; 2022 Dec; 56(12):1289-1298. PubMed ID: 35499336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Direct Oral Anticoagulants on Anti-Factor Xa Measurements Utilized for Monitoring Heparin.
    Macedo KA; Tatarian P; Eugenio KR
    Ann Pharmacother; 2018 Feb; 52(2):154-159. PubMed ID: 28862013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.
    Beyer J; Trujillo T; Fisher S; Ko A; Lind SE; Kiser TH
    Clin Appl Thromb Hemost; 2016 Jul; 22(5):423-8. PubMed ID: 26842561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time.
    Kindelin NM; Anthes AM; Providence SM; Zhao X; Aspinall SL
    Ann Pharmacother; 2021 May; 55(5):575-583. PubMed ID: 32964730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of bleeding with factor Xa inhibitors versus unfractionated heparin in patients with acute kidney injury.
    Aprilliano B; Giuliano C; Paxton RA; Edwin SB
    Pharmacotherapy; 2023 Feb; 43(2):129-135. PubMed ID: 36588500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between activated clotting time and anti-activated factor X activity for the monitoring of unfractionated heparin therapy in patients with aortic aneurysm undergoing an endovascular procedure.
    Dieplinger B; Egger M; Luft C; Hinterreiter F; Pernerstorfer T; Haltmayer M; Mueller T
    J Vasc Surg; 2018 Aug; 68(2):400-407. PubMed ID: 29571622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transitioning hospitalized patients from rivaroxaban or apixaban to a continuous unfractionated heparin infusion: A retrospective review.
    Smith AR; Dager WE; Gulseth MP
    Am J Health Syst Pharm; 2020 Aug; 77(Suppl 3):S59-S65. PubMed ID: 32719867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of unfractionated heparin protocols using antifactor Xa monitoring or activated partial thrombin time monitoring.
    Frugé KS; Lee YR
    Am J Health Syst Pharm; 2015 Sep; 72(17 Suppl 2):S90-7. PubMed ID: 26272899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systemwide Approach for Navigating the Dilemma of Oral Factor Xa Inhibitor Interference With Unfractionated Heparin Anti-Factor Xa Concentrations.
    Levito MN; Coons JC; Verrico MM; Szymkowiak A; Legler B; Dueweke EJ; Kane-Gill SL
    Ann Pharmacother; 2021 May; 55(5):618-623. PubMed ID: 32885997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From Activated Partial Thromboplastin Time to Antifactor Xa and Back Again.
    May JE; Siniard RC; Taylor LJ; Marques MB; Gangaraju R
    Am J Clin Pathol; 2022 Mar; 157(3):321-327. PubMed ID: 34562001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.
    Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V
    Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can an anti-Xa assay for unfractionated heparin be used to assess the presence of rivaroxaban in critical situations?
    Shin H; Koh EH; Lee GW; Song HN; Kim HY; Park S
    J Vasc Surg Venous Lymphat Disord; 2020 Sep; 8(5):741-747. PubMed ID: 32113855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion.
    Zochert S; Oltman KM; Elgersma BM; Hellwig TR; Gulseth MP
    Am J Health Syst Pharm; 2019 Apr; 76(8):505-511. PubMed ID: 31361865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
    Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
    J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interference of oral anti-Xa anticoagulants during monitoring of unfractionated heparin treatments: practical and future attitudes].
    Melicine S; Maucorps L; Eschwège V; Carré J; Helley D; Gouin-Thibault I; Gendron N; Nédélec-Gac F; Mauge L
    Ann Biol Clin (Paris); 2024 Jun; 82(2):129-138. PubMed ID: 38832688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Use of heparin calibrated anti-Xa assay for apixaban and rivaroxaban measurement in the context of regional telestroke activity].
    Delassasseigne C; Leroux C; Renou P; Girard D; Lafargue A; Morel S; Belotti PT; Weinmann L
    Ann Biol Clin (Paris); 2023 Jul; 81(3):269-279. PubMed ID: 37329142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
    Morishima Y; Honda Y; Kamisato C; Shibano T
    Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.